Literature DB >> 7488251

Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals.

A Comoglio1, A Tomasi, S Malandrino, G Poli, E Albano.   

Abstract

Ethanol metabolism by cytochrome P4502E1 (CYP2E1) produces free radical intermediates, identified as hydroxyethyl radicals. We have observed that in vitro addition or in vivo pretreatment of rats with Silipide, a new 1:1 complex of silybin with phosphatidyl-choline, is able to decrease the spin trapping of hydroxyethyl radicals in microsomes from chronic alcohol-fed rats. This effect is not due to an interference with the metabolism of ethanol by CYP2E1, but is rather related to the capacity of the silybin molecule to scavenge hydroxyethyl radicals. However, such an effect is lost when pure silybin in amounts comparable to those present in Silipide is administered instead, due to the low bioavailability of uncomplexed flavonoid. Further experiments in vivo have shown that Silipide administration also decreases hydroxyethyl radical signals detectable in the bile of rats acutely treated with ethanol. The ability of Silipide to scavenge ethanol-derived radicals along with its antioxidant activity suggests that this drug might be potentially useful in counteracting free radical-mediated injuries involved in the development of liver damage caused by alcohol abuse.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488251     DOI: 10.1016/0006-2952(95)02001-s

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

Review 2.  Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?

Authors:  Moon-Sun Kim; Madeleine Ong; Xianqin Qu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells.

Authors:  Alessandro Federico; Valeria Conti; Giusy Russomanno; Marcello Dallio; Mario Masarone; Paola Stiuso; Concetta Tuccillo; Michele Caraglia; Valentina Manzo; Marcello Persico; Amelia Filippelli; Carmelina Loguercio
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

Review 4.  Herb-drug interactions: a literature review.

Authors:  Zeping Hu; Xiaoxia Yang; Paul Chi Lui Ho; Sui Yung Chan; Paul Wan Sia Heng; Eli Chan; Wei Duan; Hwee Ling Koh; Shufeng Zhou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

Review 6.  Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B.

Authors:  F Wei; S-K Liu; X-Y Liu; Z-J Li; B Li; Y-L Zhou; H-Y Zhang; Y-W Li
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-12-18       Impact factor: 3.267

7.  Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity.

Authors:  Suvadra Das; Partha Roy; Runa Ghosh Auddy; Arup Mukherjee
Journal:  Int J Nanomedicine       Date:  2011-06-22

Review 8.  Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer.

Authors:  Maryam Fallah; Amirhossein Davoodvandi; Shahin Nikmanzar; Sarehnaz Aghili; Seyed Mohammad Ali Mirazimi; Michael Aschner; Amir Rashidian; Michael R Hamblin; Mohsen Chamanara; Navid Naghsh; Hamed Mirzaei
Journal:  Biomed Pharmacother       Date:  2021-08-13       Impact factor: 6.529

9.  Enhanced oral bioavailability of silymarin using liposomes containing a bile salt: preparation by supercritical fluid technology and evaluation in vitro and in vivo.

Authors:  Gang Yang; Yaping Zhao; Yongtai Zhang; Beilei Dang; Ying Liu; Nianping Feng
Journal:  Int J Nanomedicine       Date:  2015-10-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.